Innovation and resilience in times of crisis - Civil society advocacy for drug policy reform under the COVID-19 pandemic
Part II of this publication, focused on the harm reduction response, is available here.
By Dania Putri, Consultant
In March 2020, the World Health Organization (WHO) characterised COVID-19 as a pandemic, prompting governments around the globe to declare a state of emergency and/or implement a wide variety of policies and programmes in order to curb outbreaks, minimise mortality rates, and maintain public safety and order. These include, but are not limited to, different forms of travel and/or movement restrictions (such as lockdowns and quarantine), closure of premises deemed non-essential, and restrictions on gatherings and/or events. Such measures have caused significant changes in public life, public services, governance, democracy and policymaking processes around the world – as well as having serious short- and long-term economic implications.
One additional impact of these measures is the disruption of various channels and dynamics of advocacy conducted by civil society organisations. Prior to the global pandemic, civil society organisations were already facing increasing constraints and shrinking space for advocacy. The COVID-19 pandemic has certainly accelerated this downward trend of intensifying repression, in some cases combined with various forms of disinformation, abuse of power and violence. Meanwhile, some civil society actors have been pushed to adapt their ways of working while remaining resilient as they face impacts such as increased workload and/or pressure (amid having less in-person interactions, working from home, and growing demand for services), uncertainty around financial and organisational sustainability, and health concerns, among others.
Aiming to better understand and support the network to respond to these emerging challenges, especially with regard to advocacy for drug policy reform centred on human rights and public health, the IDPC Secretariat initiated a process of documenting and analysing the experiences of civil society and governmental actors working in the context of the COVID-19 pandemic. This goes in line with the IDPC mandate to advocate for civil society inclusion in drug policy debates, as well as to support civil society, and our members in particular, in navigating this new policy landscape.